-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
India Imposes 162.5% Duty on Bulk Scotch Imports Amid UK Trade Pact Dispute
-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
President Trump Clears the Path for Medical Marijuana Reform - Now Will DEA's Terry Cole Act?
WASHINGTON, DC / ACCESS Newswire / September 15, 2025 / In a decisive move to unwind Biden era regulatory gridlock, President Donald J. Trump's Department of Justice has withdrawn 16 pending rule makings and 38 projected rules - including the Drug Enforcement Administration's most critical marijuana related initiatives. The action strips away the DEA's last procedural excuses for blocking legitimate medical cannabis research.

For MMJ International Holdings and its subsidiaries MMJ BioPharma Cultivation and MMJ BioPharma Labs, the implications are immediate: DEA Administrator Terrance "Terry" Cole now faces a clear choice - approve compliant applications or continue a blockade that the Supreme Court has already branded unconstitutional.
DEA's Cover Story Just Collapsed
For years, DEA officials told courts, Congress, and companies that marijuana research and cultivation rules were "in process." Those proposals - RINs 1117-AB83, 1117-AB50, 1117-AB77, and 1117-AB86 - served as a shield to justify seven years of inaction. With Trump's Executive Order 14192 ("Unleashing Prosperity Through Deregulation"), those rules are gone.
"This DOJ notice proves what we've said for years: the DEA kept MMJ and other companies in limbo by pointing to phantom rulemakings. Those rules will be withdrawn. There are no more excuses," said Duane Boise, President & CEO of MMJ BioPharma. "Administrator Terry Cole can approve our registration today under the Controlled Substances Act and let science move forward. The longer he waits, the more patients suffer."
The Stakes: Patients, Law, and Science
MMJ BioPharma applied in 2018 to become a DEA registered bulk manufacturer of pharmaceutical-grade cannabis for FDA authorized clinical trials in Huntington's disease and Multiple Sclerosis. The company has secured two FDA Orphan Drug Designations, built a DEA-specification facility, and passed inspections - yet remains in regulatory limbo.
The withdrawal of RIN 1117-AB50 (DEA Hearing Regulations) underscores a deeper problem: DEA's tribunal system has been deemed unconstitutional by the Supreme Court in Axon v. FTC and Jarkesy v. SEC With AB50 off the agenda, DEA cannot claim imminent reform of its in-house courts, leaving the status quo both un-reformed and constitutionally defective.
Trump's Playbook: Patients Over Bureaucrats
By eliminating Biden's stalled rulemakings, Trump positions himself as the reformer who cut through the bureaucratic chokehold. Advocates expect the White House to soon advance a major cannabis policy package that could:
Codify medical marijuana research protections.
Push DEA to act on existing applications like MMJ's.
Clarify the role of FDA-approved cannabis medicines in U.S. healthcare.
"President Trump and Administrator Terry Cole don't have to choose between marijuana chaos and prohibition," Boise added. "The real choice is between Big Weed and FDA-regulated cannabis medicine. MMJ has already built the science, manufactured the capsule, and is prepared for clinical trials. All we're asking is for the DEA to finally follow its own law."
Moving Forward
With the rule making cover gone, all eyes are on Administrator Terry Cole. Will he honor Trump's deregulatory order and approve medical cannabis research - or cling to a system already judged unconstitutional? For the thousands of patients awaiting new therapies, the clock is ticking
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
T.Wright--AT